10+ years
of clinical experience
in dermatology2
More than
patients have been prescribed HUMIRA for plaque psoriasis since its FDA approval in 2008.3,4
MODERATE TO SEVERE CHRONIC
PLAQUE PSORIASIS (Ps)
More than 250,000 patients have been prescribed HUMIRA for Ps since its FDA approval in 2008.3,4
ACTIVE
PSORIATIC ARTHRITIS (PsA)
An every-other-week dosing schedule, with no loading dose.1
MODERATE TO SEVERE
HIDRADENITIS SUPPURATIVA (HS)
More than 15,000 patients have been prescribed HUMIRA for HS since its FDA approval in 2015.5
Dramatic skin clearance in Ps
HUMIRA clinical data includes dramatic skin clearance at 16 weeks for most patients and a well-studied safety profile in moderate to severe Ps.1,6-10
Powerful protection against further joint damage
HUMIRA clinical data includes inhibition of radiographic progression at week 48 vs placebo at week 24 and improvement of signs and symptoms at week 12 in many patients.1
In 2019, over
97%
of National Commercial, Medicare Part D, and Medicaid patients have access to HUMIRA as a preferred, first-line† targeted immunomodulator (TIM) on formulary.11
†Formulary Definitions: Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit, or are placed on a higher tier. First-line refers to a preferred or parity formulary status.
The 1st and only FDA-approved treatment for HS
Only HUMIRA is FDA-approved to provide clinically meaningful improvement in moderate to severe HS.1,12